Analysts Expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to Post -$0.41 EPS

Analysts expect Kala Pharmaceuticals Inc (NASDAQ:KALA) to report ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Kala Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.56). Kala Pharmaceuticals posted earnings of ($0.70) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.4%. The company is scheduled to issue its next quarterly earnings results on Tuesday, August 4th.

On average, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.72) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($1.10). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.27) per share, with EPS estimates ranging from ($2.27) to ($0.84). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.03). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $2.49 million. Kala Pharmaceuticals had a negative return on equity of 132.08% and a negative net margin of 1,578.64%.

A number of equities analysts recently weighed in on KALA shares. HC Wainwright reissued a “buy” rating and issued a $17.00 price target (up from $14.00) on shares of Kala Pharmaceuticals in a report on Wednesday. ValuEngine raised shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. JPMorgan Chase & Co. upped their price objective on shares of Kala Pharmaceuticals from $14.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday. Zacks Investment Research raised shares of Kala Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Wednesday, May 20th. Finally, Wedbush reaffirmed a “buy” rating and set a $35.00 price objective on shares of Kala Pharmaceuticals in a report on Monday, May 11th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $19.33.

Shares of NASDAQ:KALA traded up $0.06 during midday trading on Friday, reaching $12.31. The company had a trading volume of 894,453 shares, compared to its average volume of 1,259,511. The company’s 50 day moving average price is $10.85 and its 200 day moving average price is $6.92. The company has a current ratio of 12.17, a quick ratio of 11.87 and a debt-to-equity ratio of 0.50. The stock has a market cap of $663.57 million, a P/E ratio of -4.83 and a beta of 0.26. Kala Pharmaceuticals has a 52-week low of $3.24 and a 52-week high of $13.55.

In related news, COO Todd Bazemore purchased 10,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $57,500.00. Following the completion of the transaction, the chief operating officer now directly owns 10,000 shares in the company, valued at approximately $57,500. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Rajeev M. Shah purchased 6,337,135 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were bought at an average price of $7.89 per share, for a total transaction of $49,999,995.15. The disclosure for this purchase can be found here. Corporate insiders own 30.77% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in KALA. Citigroup Inc. increased its position in shares of Kala Pharmaceuticals by 217.5% during the fourth quarter. Citigroup Inc. now owns 7,379 shares of the company’s stock valued at $27,000 after buying an additional 5,055 shares during the period. Bank of Montreal Can increased its position in shares of Kala Pharmaceuticals by 334.2% in the fourth quarter. Bank of Montreal Can now owns 8,928 shares of the company’s stock worth $34,000 after purchasing an additional 6,872 shares during the last quarter. Nisa Investment Advisors LLC bought a new position in shares of Kala Pharmaceuticals in the first quarter worth approximately $44,000. Tower Research Capital LLC TRC increased its position in shares of Kala Pharmaceuticals by 196.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 12,131 shares of the company’s stock worth $45,000 after purchasing an additional 8,033 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Kala Pharmaceuticals by 82.2% in the first quarter. Victory Capital Management Inc. now owns 7,359 shares of the company’s stock worth $65,000 after purchasing an additional 3,320 shares during the last quarter. Hedge funds and other institutional investors own 73.60% of the company’s stock.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Featured Story: Day Trading

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.